Buy Crypto Markets Spot FuturesMU Earn Event Center

Merck KGaA's agreement to buy Bio-Techne for $11.3 billion strengthens its hold in life sciences, especially drug discovery and gene therapy. The post Germany’sMerck KGaA's agreement to buy Bio-Techne for $11.3 billion strengthens its hold in life sciences, especially drug discovery and gene therapy. The post Germany’s

Germany’s Merck Pumps Up Life Sciences Biz with $11.3B Bio-Techne Deal

Author: The Daily Upside

Source: The Daily Upside

2026/06/26 12:01

3 min read

BIO$0.02949+1.90%

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Darmstadt, Germany-based Merck is taking a trip to the Twin Cities to buy Minnesota-based Bio-Techne. The $11.3 billion deal would be Merck’s biggest acquisition in more than 10 years as the drugmaker expands under new CEO Kai Beckmann.

Bio-Techne spiked nearly 20% Thursday on the Nasdaq, while Merck KGaA, which hails from Germany as opposed to the US’s Merck & Co., popped about 5%. (While the companies share a name and historical roots, they’ve been separate businesses since the early 20th century and are competitors.)

The acquisition would strengthen Merck’s foothold in life sciences, especially drug discovery and gene therapy. Merck, meanwhile, could give Bio-Techne the backing it needs to compete in a consolidating sector.

David Seeks Leg Up From Goliath

The biotech sector surged during COVID-19, and Bio-Techne benefited, with its shares spiking throughout 2020 and peaking in 2021. Its focus on medical research and diagnostic tools positioned it to benefit from the pandemic. But as the world healed, capital pouring into life sciences dried up. Bio-Techne shares were sitting at less than half their 2021 record before yesterday’s boost.

Big Pharma is taking the opportunity to scoop up smaller players struggling to stay afloat in the less-liquid environment:

Merck’s deal comes after activist investor Ananym Capital Management ramped up pressure last week on Bio-Techne to consider a sale to a pharma giant. Ananym argued it could leverage a larger peer’s resources to scale its sales faster and cheaper. Beckmann said the sale had been stewing for longer than that. Merck expects the tie-up to yield about $159 million in cost savings over three years.
The Merck chief expects more consolidation to follow. That’s already been happening throughout the industry, with fellow biotech companies Thermo Fisher Scientific and Danaher spending billions to scoop up life sciences specialists earlier this year.

Buying Bio: Taking over Bio-Techne would expand Merck’s share of the life sciences market and its overall US footprint (it would be one of Minnesota’s largest-ever acquisitions). Bio-Techne could give Merck an edge in drug discovery with its vast catalog of proteins and antibodies used for research, as well as lab tools — a $27 billion market opportunity, according to Merck’s Life Sciences chief. Last year, Merck bought SpringWorks Therapeutics for $3.9 billion, making another inroad into a US market that Beckmann has called very attractive. But other companies aren’t sitting still in the meantime, with biotech mergers and acquisitions showing signs of building momentum this year.

The post Germany’s Merck Pumps Up Life Sciences Biz with $11.3B Bio-Techne Deal appeared first on The Daily Upside.

Market Opportunity

BIO Protocol Price(BIO)

$0.02949

$0.02949$0.02949

+6.96%

USD

BIO Protocol (BIO) Live Price Chart

CHZ +28%! Will History Repeat?

0-fee opening long & short. Be ready for any move!

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

Tags:

#Strong #Based #would #Amp #Sector